TZC 8159

Drug Profile

TZC 8159

Latest Information Update: 07 Jun 2005

Price : $50

At a glance

  • Originator Teikoku Hormone
  • Class Antihypertensives; Vasodilators
  • Mechanism of Action Beta-adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 24 Sep 2004 Discontinued - Preclinical for Hypertension in Japan (unspecified route)
  • 24 Sep 1997 No-Development-Reported for Hypertension in Japan (Unknown route)
  • 16 Oct 1995 This profile is new.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top